Tyvaso DPI: Drug-device characteristics and patient clinical considerations
Related Posts
Razavi AC, Bhatia HS, Dardari ZA, Mehta A, Nasir K, Blankstein R, Isiadinso I, Quyyumi AA, Vaccarino V, Fialkow JA, Khoury MJ, Coronado F, Budoff[...]
Hashmi TM, Shafiq A, Zia R, Ashraf H, Burhan M, Ahmed M, Mesmar A, Ahmed R, Fonarow GC. Recombinant Human Pro-Urokinase vs. Alteplase Within 4.5[...]
Reddy VY, Gerstenfeld EP, Schmidt B, Andrade JG, Nair D, Natale A, Saliba W, Sommer P, Metzner A, Verma A, Hounshell T, Amin A, Gentlesk[...]